Ranbaxy now faces product bans in Europe

Six years after the FDA banned products from a Ranbaxy Laboratories plant in Dewas, India, the European Commission and Germany have restricted imports of sterile drugs from the facility. Regulators have banned Ranbaxy's injectable versions of its cephalosporin antibiotics following an inspection earlier this year of the company's plant in central India. The Dewas plant was one of two Ranbaxy facilities the FDA banned in 2008 when issues were first brought to its attention by a whistleblower. The Indian drugmaker paid $500 million in penalties last year to settle litigation with the Justice Department tied to shortcomings found at the facilities, but in the last couple of years, the FDA has banned two more Ranbaxy plants for similar issues. Story